Skip to main content

STANDARD BIOTOOLS INC

For the period ended Dec 31, 2024. Filed Mar 11, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 11, 2025

LAB$0.69+9.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

STANDARD BIOTOOLS INC.
Dated: March 10, 2025By:/s/ Michael Egholm, Ph.D.
Michael Egholm, Ph.D.
President and Chief Executive Officer

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Egholm, Ph.D., and Alex Kim, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Form 10-K, and any amendments thereof, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SignatureTitleDate
/s/Michael Egholm, Ph.D.President and Chief Executive Officer (Principal Executive Officer); DirectorMarch 10, 2025
Michael Egholm, Ph.D.
/s/Alex KimChief Financial Officer (Principal Financial and Accounting Officer)March 10, 2025
Alex Kim
/s/ Tom CareyChairman of the Board of DirectorsMarch 10, 2025
Tom Carey
/s/ Fenel M. EloiDirectorMarch 10, 2025
Fenel M. Eloi
/s/ Eli CasdinDirectorMarch 10, 2025
Eli Casdin
/s/ Kathy HibbsDirectorMarch 10, 2025
Kathy Hibbs
/s/ Troy CoxDirectorMarch 10, 2025
Troy Cox
/s/ Frank Witney, Ph.D.DirectorMarch 10, 2025
Frank Witney, Ph.D.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.